Do women unfairly pay more for prescriptions? According to Senators Olympia Snow (R-ME) and Harry Reid (D-NV), who introduced the Equity in Prescription Insurance and Contraceptive Coverage Act, they do.
Do women unfairly pay more for prescriptions? According to Senators Olympia Snow (R-ME) and Harry Reid (D-NV), who introduced the Equity in Prescription Insurance and Contraceptive Coverage Act, they do.
The cost of birth control pills is not covered by many large group insurance plans. As a result, women of reproductive age spend 63% more than men on out-of-pocket health costs, said Snow. And that, she insisted, is not fair.
"It is simply not right that while the vast majority of insurers cover prescription drugs, half of large group plans exclude coverage of contraceptives," she said. "...Only one-third cover oral contraceptives."
If passed, the bipartisan bill would prohibit plans offering drug coverage from excluding or restricting benefits for FDA-approved prescription contraceptive drugs or devices. The plans would be required to cover outpatient contraceptive services if they provide benefits coverage for other outpatient services.
In addition, health plans could only impose cost-sharing and deductible requirements for contraceptives or outpatient contraceptive services equal to those imposed for other prescription or outpatient benefits.
The bill, which would take effect on January 1, 1998, would be passed as an amendment to ERISA. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.